Atnaujinta: 2024.07.03 12:18 (GMT+3)

GRD: About the invitation to submit application for the acquisition of pharmaceutical company “Jelfa

2005.10.12, Grindeks, RIG
Grindeks                                                        12.10.2005

JSC Grindeks informs about the invitation to repeatedly submit its application
for the acquisition of the shares of pharmaceutical company “Jelfa S.A”

On October 5, JSC Grindeks received an official letter from the Industrial
Development Agency (IDA) of Poland with the invitation to repeatedly submit
its application for the acquisition of the share stock making 47, 83% of
total Jelfa’s share capital.


After the evaluation of the previously submitted applications concerning
price proposal and other conditions Industrial Development Agency (IDA) of
Poland has accepted JSC Grindeks as one of the applicants for the acquisition
of the share capital owned by the State institutions. Participation in the
auction for the above mentioned 47,83% share capital is set to be in several
stages. First stage of this auction was beneficial for the JSC Grindeks.

As it is mentioned before JSC Grindeks on June 6 as a response to the letter
from IDA inviting Grindeks to take part in the process of privatization of
Jelfa’s share capital belonging to the State institutions submitted its
application at the Industrial Development Agency (IDA) of Poland expressing
an interest to purchase the share capital of the pharmaceutical company
Jelfa S.A.

For this moment state institution owned shares 47.83 % is divided into - 26.1%
of „Jelfa” share capital belongs to the Industrial Development Agency (IDA) of
Poland, 3.9% to the Ministry of State Treasury, 16.7% to the State Insurance
Joint Stock Company.


Information prepared by:
Finance and Administrative director
JSC Grindeks
Office: 7083250,
GSM: 9226767
e-mail: janis_romanovskis@grindeks.lv

Vertybiniai popieriai

Akcijos
Obligacijos
Fondai

Rinkos informacija

Statistika
Prekyba
Indeksai
Aukcionai

Reguliavimas

Taisyklės ir nuostatos
Priežiūra

Kaip pradėti

Įmonėms
Investuotojams
Nariams
First North sertifikuotiems PATARĖJAMS

Naujienos

Nasdaq naujienos
Emitento naujienos
Kalendorius

Apie mus

Nasdaq Baltijos rinkoje
Biurai